Want to join the conversation?
$SJM 1Q16 PR: "We are off to a solid start this fiscal year, with net sales increasing 47% and non-GAAP operating income growth of 37%. We are on track to achieve our full year expectations for net sales and earnings, and are confident about the initiatives we have in place to support future growth," said Richard Smucker, Chief Executive Officer.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.